Abstract
Percutaneous cranial irradiation (PCI) has had benefit for patients with limited disease small cell lung cancer (SCLC). The findings of a study now indicate that PCI also has benefit in the setting of extensive disease-SCLC, where the risk of brain metastases is high. This article discusses the findings of a study in which PCI led to a significant reduction in the risk of symptomatic brain metastases and a significant prolongation of survival.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
